Neurologic Injury in Patients Treated With Extracorporeal Membrane Oxygenation for Postcardiotomy Cardiogenic Shock
There is considerable interinstitutional variation in the proportion of neurologic injury in PC-ECMO-treated adults. Well-known risk factors for stroke are not associated with neurologic injury in this setting.
Predicting Parameters for Successful Weaning from Veno‐Arterial Extracorporeal Membrane Oxygenation in Cardiogenic Shock
The present findings indicate that LVETc∕PAWP is a potential predictor of successful weaning from VA‐ECMO.
Use of Dialysis, Tracheostomy, and Extracorporeal Membrane Oxygenation Among 240,392 Patients Hospitalized With COVID-19 in the United States
Although less than one percent of patients undergo tracheostomy and ECMO, the absolute numbers of patients who have undergone these interventions is substantial and can be expected to continue grow given the continuing spread of the COVID-19.
Extracorporeal Membrane Oxygenation (ECMO) in Patients with COVID-19: A Rapid Systematic Review of Case Studies
ECMO plays an important role in the stabilization and survival critically ill patients with COVID-19, but the usefulness of ECMO in reducing the mortality of severe ARDS caused by COVID-19 was limited.
Advanced Therapies and Extracorporeal Membrane Oxygenation for The Management of High-Risk Pulmonary Embolism
The use of ECMO with anticoagulation seems promising in high-risk PE when systemic thrombolysis is contraindicated, though quality of evidence is low and future studies are urgently needed to better define its optimal use.
Intraoperative Off-Label Reversal of Apixaban by Andexanet Alfa while on VA-ECMO Immediately After Emergent Surgery for Acute Type A Aortic Dissection
There is currently no information available on either safety issues or efficacy related to the off-label use of andexanet alfa when given after prior administration of prothrombin complex concentrate, which has been discouraged so far, and in patients on venoarterial extracorporeal membrane oxygenation (VA-ECMO).
A Case of Cytokine Hemofiltration and Extracorporeal Life Support as Treatment of Coronavirus Disease 2019 (COVID-19) Respiratory Failure
A hyperactive immune response has been implicated in COVID-19 respiratory failure. Hemofiltration with a membrane designed to remove cytokines offers a potential avenue for treatment.
Blood Transfusion Threshold in Patients Receiving Extracorporeal Membrane Oxygenation Support for Cardiac and Respiratory Failure—A Systematic Review and Meta-Analysis
The present study did not resolve uncertainty as to transfusion management in ECMO, although several studies (most of them in VV ECMO) demonstrated that a restrictive threshold has acceptable outcomes in single-center cohorts.
How I Approach Membrane Lung Dysfunction in Patients Receiving ECMO
The decision to exchange a ML is complex and without clear guidelines. In this manuscript, we outline a physiologic approach to troubleshooting this common yet high risk event.
Inter-hospital COVID ECMO Air Transportation
The detailed protocol is described alongside initial data of its use. To date, 14 patients have been placed on ECMO support at an outside facility and successfully transported via helicopter to our hub hospital using this protocol.
Safely Repositioning Dual-Lumen ECMO Cannulas with A Transfemoral Lasso Snare
We describe three patients who successfully had dual-lumen cannulas repositioned without cessation of ECMO using a transfemoral “lasso” technique.
Role of Extracorporeal Membrane Oxygenation in Critically Ill COVID-19 Patients and Predictors of Mortality
The present study suggests that ECMO is a potentially lifesaving treatment for selected critically ill COVID‐19 patients. Considering IL‐6 and NT‐per‐BNP, in addition to the RESP score, may enhance outcome predictions.